Therapeutic candidates can only advance as far as their engineering allows. For every molecule that reaches the clinic, hundreds of others are synthesised, tested, and discarded. The problem is rarely that the target was wrong, but rather that the tools used to optimise antibody and TCR affinity, specificity, functional potency, and developability required for a clinical candidate are inefficient. Conventional biologics engineering approaches - whether for antibodies or T cel

In this blog post, we share the story of how AI-guided TCR engineering worked in practice, enabling the optimization of a TCR therapeutic in just weeks, rather than months.